



PRESS RELEASE

11 April 2006

SYNAIRGEN PLC

Board changes

The Board of Synairgen, the drug discovery company focused on identifying and out-licensing new pharmaceutical products which address the underlying causes of asthma and chronic obstructive pulmonary disease ('COPD'), announces that it has appointed Dr David Bruce Campbell as a non-executive director with immediate effect. He replaces David Norwood who has today stepped down from the Board to devote more time to IP2IPO Group plc.

Bruce Campbell (61) is currently non-executive Chairman of Proximagen Neuroscience plc, Chief Scientific Officer and a director of IP2IPO Group plc, a director of Modern Biosciences plc and a non-executive director of iQur Limited and Proximagen Limited.

Formerly, Dr Campbell was Senior VP of International Development at Neurocrine Biosciences, Inc. ('Neurocrine'). Prior to joining Neurocrine, Dr Campbell worked for 27 years at Servier (United Kingdom), latterly as Scientific Director. In addition, he has also been a director and European Chairman of the Drug Information Association and a member of the European ICH Safety Working Party. Dr Campbell is a visiting Professor in Pharmacology at King's College, London.

There are no further disclosures to be made in accordance with Schedule 2(g) of the AIM Rules.

Simon Shaw, Chairman, commented:

"We are delighted that Bruce is joining the Board of Synairgen. His extensive international experience in pharmaceutical drug development will be valuable to Synairgen at this exciting time in our development.

"On behalf of the Board, I would like to thank David Norwood for his help and guidance as a non-executive director of Synairgen since its formation in late 2003."

-Ends-

For further information, please contact:

Synairgen
Richard Marsden, Managing Director Tel: 02380 512 800

Hogarth Partnership
Melanie Toyne-Sewell / Georgina Briscoe Tel: 020 7357 9477